Tricuspid Regurgitation clinical trials

Explore recruiting tricuspid regurgitation clinical trials.

Recruiting tricuspid regurgitation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tricuspid Regurgitation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

LEONARD.LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction (LEONARD)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of JTT-861 Administered for 12 Weeks in Subjects with Heart Failure with Reduced Ejection Fraction (POWER-HF)

Poland, Spain, Romania, Bulgaria, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

PERCUTANEOUS EMBOLECTOMY, LOW DOSE THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBOLISM

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Targeting branched-chain amino acid oxidation to improve glycaemic control in patients with type 2 diabetes

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

The Effect of Mitapivat on Cerebral Perfusion and Oxygen Metabolism in Sickle Cell Disease

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Tricuspid Regurgitation trials by city

Tricuspid Regurgitation in Toronto Tricuspid Regurgitation in Vancouver Tricuspid Regurgitation in Montreal Tricuspid Regurgitation in Calgary Tricuspid Regurgitation in Edmonton Tricuspid Regurgitation in Ottawa Tricuspid Regurgitation in Winnipeg Tricuspid Regurgitation in Quebec City Tricuspid Regurgitation in Hamilton Tricuspid Regurgitation in Kitchener Tricuspid Regurgitation in London Tricuspid Regurgitation in Halifax Tricuspid Regurgitation in New York Tricuspid Regurgitation in Los Angeles Tricuspid Regurgitation in Chicago Tricuspid Regurgitation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease